Twice-daily fractionation of external irradiation with brachytherapy in bulky carcinoma of the cervix. Phase I/II study of the radiation therapy oncology group 88—05

✍ Scribed by Ritsuko Komaki; Thomas F. Pajak; Victor A. Marcial; Marvin Rotman; Perry W. Grigsby; Steven A. Leibel; Patricia J. Eifel

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 595 KB
• Volume: 73
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19940515)73:10<2619::aid-cncr2820731025>3.0.co;2-p

✦ Synopsis

1.9% at 1 year, and 6.3% at 2 and 3 years. Of 80 patients evaluated for response, 80% had complete disappearance of disease. Comparisons with historical rates of late toxicity with standard fractionation (STD) revealed similar results in spite of higher total doses with HFX. Comparisons between historical STD and HFX also revealed equivalent rates of pelvic tumor control, Grade 3-4 toxicity, and survival at 3 years.

Conclusions. Results suggest that combined with brachytherapy, HFX at total parametrial doses 10% above those used with STD was tolerated and at least as effective as STD. Further study with higher doses and extended fields is indicated. Comparisons of long term (5- plus years) survival and late-effects rates with STD versus HFX are planned.